PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small Cell Lung
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT00174356
- Locations
- 🇨🇦
Pfizer Investigational Site, Hamilton, Ontario, Canada
A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
Phase 1
Completed
- Conditions
- Patients With Pace Makers But no Evidence of Ischemic Heart Disease
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00174512
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
Phase 2
Completed
- Conditions
- Impotence
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00174486
Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age
Phase 2
Completed
- Conditions
- Infant, Very Low Birth WeightGrowth Hormone Therapy
- Interventions
- Other: Control Arm
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT00174460
- Locations
- 🇩🇪
Pfizer Investigational Site, Tuebingen, Germany
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
Not Applicable
Completed
- Conditions
- Psychotic DisordersSchizophrenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-07-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00174200
- Locations
- 🇷🇺
Pfizer Investigational Site, Moscow, Russian Federation
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00163618
- Locations
- 🇦🇹
Freistädter Strasse 290, Linz, Austria
🇦🇹Bahnhofstraße 9, Hermagor, Austria
🇦🇹Conrad-von-Hoetzendorf-Strasse, Voitsberg, Austria
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
Phase 4
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00163540
- Locations
- 🇧🇪
SGS Biopharma Research Unit Stuivenberg, Antwerp, Belgium
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 98
- Registration Number
- NCT00163189
- Locations
- 🇫🇷
Centre de Perharidy, Roscoff Cedex, France
🇫🇷Hôpital Lenval, Nice, France
🇫🇷CHU Timone Enfants, Marseille Cedex 5, France
Growth Retardation In Children With Special Pathological Conditions Or Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00163215
- Locations
- 🇫🇷
Pfizer Investigational Site, Vandoeuvre Les Nancy Cedex, France
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
Phase 4
Completed
- Conditions
- Encephalitis, Tick-borne
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00161954
- Locations
- 🇧🇪
SGS Biopharma Research Unit Stuivenberg, Antwerp, Belgium
© Copyright 2025. All Rights Reserved by MedPath